KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Other Non-Current Assets: 2019-2024

Historic Other Non-Current Assets for Royalty Pharma (RPRX) over the last 6 years, with Dec 2024 value amounting to $33.5 million.

  • Royalty Pharma's Other Non-Current Assets rose 102.35% to $86.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $86.6 million, marking a year-over-year increase of 102.35%. This contributed to the annual value of $33.5 million for FY2024, which is 414.17% up from last year.
  • As of FY2024, Royalty Pharma's Other Non-Current Assets stood at $33.5 million, which was up 414.17% from $6.5 million recorded in FY2023.
  • In the past 5 years, Royalty Pharma's Other Non-Current Assets ranged from a high of $33.5 million in FY2024 and a low of $4.1 million during FY2021.
  • In the last 3 years, Royalty Pharma's Other Non-Current Assets had a median value of $29.6 million in 2022 and averaged $23.2 million.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first skyrocketed by 614.81% in 2022, then slumped by 77.99% in 2023.
  • Royalty Pharma's Other Non-Current Assets (Yearly) stood at $10.0 million in 2020, then plummeted by 58.54% to $4.1 million in 2021, then soared by 614.81% to $29.6 million in 2022, then tumbled by 77.99% to $6.5 million in 2023, then spiked by 414.17% to $33.5 million in 2024.